Full PPARγ agonists, such as TZD drugs, are potent insulin sensitizers for the treatment of type 2 diabetes mellitus, but their side effects have been problematic, including fluid retention, edema, bone loss, and weight gain30. The gene discussed is INS; the disease is type 2 diabetes mellitus.